PharmaEssentia Announces Updated NCCN Clinical Practice Guidelines Include ropeginterferon alfa-2b-njft (BESREMi®) for ...
Treatment for stage 2 essential thrombocythemia is highly personalized. Not every patient requires medication right away, and ...
In a significant shift for the treatment landscape of essential thrombocythemia (ET), the US National Comprehensive Cancer Network (NCCN) has designated ropeginterferon alfa-2b-njft (Besremi) as a ...
Findings showed 42.9% of P1101-treated patients achieved durable responses at both 9 and 12 months compared with 6% in those treated with anagrelide (P =.0001). Topline data were announced from a ...
The sBLA is supported by data from the phase 3 SURPASS-ET trial, as well as confirmatory data from the phase 2b EXCEED-ET trial.
Hemorrhagic events post-diagnosis in patients with ET significantly increase mortality risk, more than thrombosis or disease progression. Intracranial hemorrhage is the most lethal bleeding ...
Overexpression of the Polycythemia Rubra Vera-1 Gene in Essential Thrombocythemia Authors: Luciana Teofili, Maurizio Martini, Myriam Luongo, Antonella Di Mario, Giuseppe Leone, Valerio De Stefano, and ...
100% (29/29) of patients experienced platelet count reduction to within normal ranges (150 – 400 x 109/L). 90% (26/29) of patients achieved a platelet count of less than 400 x 109/L without ...
The FDA has accepted the supplemental Biologics License Application (BLA) for ropeginterferon alfa-2b-njft (Besremi), a ...
BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TPEx:6446), a global biopharmaceutical innovator based in Taiwan leveraging deep ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results